FR11C0038I2 - MACROCYCLIC ANALOGS, THEIR METHODS OF USE AND PREPARATION - Google Patents

MACROCYCLIC ANALOGS, THEIR METHODS OF USE AND PREPARATION

Info

Publication number
FR11C0038I2
FR11C0038I2 FR11C0038C FR11C0038C FR11C0038I2 FR 11C0038 I2 FR11C0038 I2 FR 11C0038I2 FR 11C0038 C FR11C0038 C FR 11C0038C FR 11C0038 C FR11C0038 C FR 11C0038C FR 11C0038 I2 FR11C0038 I2 FR 11C0038I2
Authority
FR
France
Prior art keywords
preparation
methods
macrocyclic analogs
analogs
macrocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0038C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0038(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of FR11C0038I1 publication Critical patent/FR11C0038I1/en
Application granted granted Critical
Publication of FR11C0038I2 publication Critical patent/FR11C0038I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention provides a compound having the formula: that is useful as an intermediate in the preparation of certain pharmaceutically active halichondrin analogs.
FR11C0038C 1998-06-17 2011-09-09 MACROCYCLIC ANALOGS, THEIR METHODS OF USE AND PREPARATION Active FR11C0038I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
EP99928746A EP1087960B1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (2)

Publication Number Publication Date
FR11C0038I1 FR11C0038I1 (en) 2011-10-14
FR11C0038I2 true FR11C0038I2 (en) 2013-01-11

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0038C Active FR11C0038I2 (en) 1998-06-17 2011-09-09 MACROCYCLIC ANALOGS, THEIR METHODS OF USE AND PREPARATION

Country Status (24)

Country Link
US (4) US6214865B1 (en)
EP (4) EP2272839B1 (en)
JP (1) JP4454151B2 (en)
KR (1) KR100798600B1 (en)
CN (1) CN1216051C (en)
AT (1) ATE502932T1 (en)
AU (1) AU762998B2 (en)
BE (1) BE2011C028I2 (en)
BR (1) BRPI9911326B8 (en)
CA (3) CA2632433C (en)
CY (2) CY1111516T1 (en)
DE (2) DE122011100031I1 (en)
DK (1) DK1087960T3 (en)
FR (1) FR11C0038I2 (en)
HK (1) HK1035534A1 (en)
HU (1) HU227912B1 (en)
IL (1) IL139960A0 (en)
LU (1) LU91854I2 (en)
NO (5) NO328280B1 (en)
NZ (1) NZ508597A (en)
PT (1) PT1087960E (en)
RU (1) RU2245335C2 (en)
WO (1) WO1999065894A1 (en)
ZA (1) ZA200007159B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
BRPI9911326B8 (en) 1998-06-17 2021-05-25 Eisai Co Ltd macrocyclic analogues and methods for their use and preparation
DE10037310A1 (en) 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
AU2003228354B8 (en) 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
JP2007500240A (en) * 2003-05-29 2007-01-11 アボット・ラボラトリーズ Continuous administration regimen with ABT-751
US20070196418A1 (en) * 2003-07-29 2007-08-23 Michael Lewis Drug delivery methods and devices
CN1993342A (en) * 2004-06-03 2007-07-04 卫材株式会社 Intermediates for the preparation of halichondrin b
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) * 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
JP6001857B2 (en) * 2008-04-04 2016-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Halichondrin B analog
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
RU2476216C1 (en) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Liposomal composition
PE20120923A1 (en) 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd PHARMACEUTICAL COMPOSITIONS INCLUDING LIPOSOMES CONTAINING ERIBULIN OR A SALT OF IT
WO2010119890A1 (en) * 2009-04-14 2010-10-21 日産化学工業株式会社 Method for producing tetrahydropyran compound and intermediate thereof
CN102803254B (en) 2010-01-26 2016-09-14 卫材R&D管理有限公司 Furo [3,2-B] pyran derivate for halichondrin b analogs synthesis
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
CN104024237B (en) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 For the preparation of method and the useful intermediate thereof of 3-((2S, 5S)-4-methylene radical-5-(3-oxopropyl) tetrahydrofuran (THF)-2-base) propanol derivative
CA2860446C (en) * 2011-12-29 2017-01-10 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
EP2831082B1 (en) * 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
AU2013353745A1 (en) 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
AR096238A1 (en) 2013-05-15 2015-12-16 Alphora Res Inc PROCESS TO PREPARE DERIVATIVES OF 3 - ((2S, 5S) -4-METHYLENE-5- (3-OXOPROPIL) TETRAHYDROFURAN-2-IL) PROPANOL AND INTERMEDIARIES USEFUL FOR THE SAME
ES2705698T3 (en) 2013-06-26 2019-03-26 Eisai R&D Man Co Ltd Combination therapy for cancer treatment comprising eribulin and lenvatinib
AU2014286880B2 (en) * 2013-07-03 2017-12-14 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
CN103483352A (en) * 2013-10-18 2014-01-01 李友香 Medicinal bulk drug for resisting tumors
CN114716453A (en) 2013-11-04 2022-07-08 卫材R&D管理有限公司 Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
EP3077399B1 (en) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
CN104860978A (en) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 Synthesis intermediates of halichondrin B analog
TW201617326A (en) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
KR20170039096A (en) * 2014-05-28 2017-04-10 에자이 알앤드디 매니지먼트 가부시키가이샤 Use of eribulin in the treatment of cancer
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
JO3783B1 (en) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd Highly pure quinoline derivative and method for producing the same
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (en) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 Intermediate for preparing eribulin and preparation method thereof
DK3263106T3 (en) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US10945990B2 (en) 2015-03-04 2021-03-16 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6840090B2 (en) 2015-05-07 2021-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Macrocyclic reactions and intermediates and other fragments useful for the synthesis of halichondrin macrolides
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN107801379B (en) 2015-06-16 2021-05-25 卫材R&D管理有限公司 Anticancer agent
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
WO2017188350A1 (en) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for inhibiting tumor growth
WO2017203459A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
KR102404629B1 (en) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 Prince Reaction and Intermediates Useful for Synthesis of Halicondine Macrolides and Analogs thereof
US20190263927A1 (en) 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (en) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Palladium-mediated ketolization
BR112019010494A2 (en) 2016-11-23 2019-09-17 Dr Reddys Laboratories Ltd process for the preparation of eribulin and intermediates thereof
ES2932832T3 (en) * 2017-01-02 2023-01-26 Yonsung Fine Chemical Co Ltd Production intermediate of eribulin mesylate, and method of producing the same
KR101991710B1 (en) 2017-12-14 2019-06-21 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
KR101880939B1 (en) 2017-01-02 2018-08-17 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same
CN108341738B (en) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
CN108341828B (en) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
KR102634732B1 (en) 2017-04-05 2024-02-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Macrocyclic compounds and their uses
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
BR112020000141A2 (en) 2017-07-06 2020-07-14 President And Fellows Of Harvard College halicondrin synthesis
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (en) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 Intermediate for preparing eribulin and preparation method thereof
EP3712141B1 (en) 2017-11-09 2023-07-12 Yonsung Fine Chemical Co., Ltd. Intermediate for preparing eribulin mesylate and method for preparing same
US11407762B2 (en) 2017-11-15 2022-08-09 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
MX2020006945A (en) 2018-01-03 2020-11-09 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof.
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020016847A2 (en) * 2018-07-20 2020-01-23 Dr. Reddy’S Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
US20210340156A1 (en) * 2018-10-09 2021-11-04 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US20220333139A1 (en) 2019-06-21 2022-10-20 Council Of Scientific And Industrial Research A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11572414B2 (en) 2019-11-07 2023-02-07 Eisai R&D Management Co., Ltd. Eribulin antibody-drug conjugates and methods of use
CN113135876A (en) * 2020-01-16 2021-07-20 南通诺泰生物医药技术有限公司 Preparation method of eribulin and intermediate thereof
JP2023511163A (en) * 2020-01-22 2023-03-16 上海森輝医薬有限公司 Drug conjugate of eribulin derivative, preparation method thereof and pharmaceutical application thereof
KR102377262B1 (en) 2020-05-11 2022-03-22 연성정밀화학(주) Crystalline Eribulin Salt
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd Process for the preparation of eribulin
CN113354659B (en) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 Synthesis of eribulin mesylate
TW202310878A (en) * 2021-07-22 2023-03-16 大陸商上海森輝醫藥有限公司 Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
BRPI9911326B8 (en) * 1998-06-17 2021-05-25 Eisai Co Ltd macrocyclic analogues and methods for their use and preparation
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
RU2010118063A (en) 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) A NEW INTERMEDIATE COMPOUND FOR SYNTHESIS OF ANALOG OF HALICHONDRIN B AND A NEW DESULPHONILATION REACTION USED FOR OBTAINING AN INTERMEDIATE COMPOUND
JP6001857B2 (en) 2008-04-04 2016-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Halichondrin B analog
CN102803254B (en) 2010-01-26 2016-09-14 卫材R&D管理有限公司 Furo [3,2-B] pyran derivate for halichondrin b analogs synthesis

Also Published As

Publication number Publication date
CA2335300C (en) 2008-10-07
EP1087960A4 (en) 2004-12-01
US6469182B1 (en) 2002-10-22
NO328280B1 (en) 2010-01-25
CY1111516T1 (en) 2014-04-09
BRPI9911326B8 (en) 2021-05-25
CY2011010I1 (en) 2014-04-09
FR11C0038I1 (en) 2011-10-14
CA2632433A1 (en) 1999-12-23
KR100798600B1 (en) 2008-01-28
AU762998C (en) 2000-01-05
CA2335300A1 (en) 1999-12-23
EP1087960A1 (en) 2001-04-04
RU2245335C2 (en) 2005-01-27
EP1087960B1 (en) 2011-03-23
CA2755266A1 (en) 1999-12-23
NO20006316L (en) 2001-02-15
NO2011026I2 (en) 2012-06-11
LU91854I2 (en) 2011-10-17
HUP0103357A2 (en) 2002-01-28
US6365759B1 (en) 2002-04-02
NZ508597A (en) 2004-01-30
US6214865B1 (en) 2001-04-10
WO1999065894A1 (en) 1999-12-23
BR9911326A (en) 2001-04-03
DE122011100031I1 (en) 2011-12-15
JP4454151B2 (en) 2010-04-21
CA2755266C (en) 2014-08-12
AU4573999A (en) 2000-01-05
EP2272840B1 (en) 2012-08-22
CN1216051C (en) 2005-08-24
JP2002518384A (en) 2002-06-25
EP2277873A1 (en) 2011-01-26
EP2272839B1 (en) 2012-08-22
NO20093217L (en) 2001-02-15
HU227912B1 (en) 2012-05-29
NO2011018I1 (en) 2011-09-26
AU762998B2 (en) 2003-07-10
BR9911326B1 (en) 2015-01-06
NO2011026I1 (en) 2012-01-09
EP2272839A1 (en) 2011-01-12
US8148554B2 (en) 2012-04-03
CA2632433C (en) 2012-02-07
US20110172446A1 (en) 2011-07-14
NO20006316D0 (en) 2000-12-12
ZA200007159B (en) 2001-12-04
EP2277873B1 (en) 2012-05-30
NO331183B1 (en) 2011-10-24
EP2272840A1 (en) 2011-01-12
HK1035534A1 (en) 2001-11-30
PT1087960E (en) 2011-06-17
DK1087960T3 (en) 2011-06-14
BE2011C028I2 (en) 2018-08-24
HUP0103357A3 (en) 2002-10-28
CN1312804A (en) 2001-09-12
NO2022019I1 (en) 2022-06-03
IL139960A0 (en) 2002-02-10
KR20010083050A (en) 2001-08-31
CY2011010I2 (en) 2014-04-09
ATE502932T1 (en) 2011-04-15
DE69943296D1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
FR11C0038I2 (en) MACROCYCLIC ANALOGS, THEIR METHODS OF USE AND PREPARATION
DK0857718T3 (en) endothelin antagonist
DE69907977D1 (en) Pyrrolobenzodiazepine
FI882390A0 (en) Tetrazoles, which are intermediates in antihypertensive compounds
ATE196913T1 (en) NOVEL PEPTIDE DERIVATIVES
DE60031400D1 (en) ISOFLAVON METABOLITE
DE69840645D1 (en) Benzamidinderivate
GR850799B (en)
BR0104358A (en) Taxane formulations having improved solubility
DK0750616T3 (en) Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds
EP1073447A4 (en) N1-modified glycopeptides
DE60121048D1 (en) PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DK0520372T3 (en) Inositol-phosphate analogues as calcium antagonists
FI901277A0 (en) 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYL PG1Z-DERIVATIVE.
PT878195E (en) USE OF A 2-AROYL-3-ARYBENZO COMPOUND (B) THYROFEN FOR REDUCING FIBRINOGEN